Telo Genomics Corp (TSE:TELO) has released an update.
Confident Investing Starts Here:
- Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter
Telo Genomics Corp has expanded its collaboration with Mayo Clinic to enhance the development of its TeloView diagnostic tests for multiple myeloma, aiming to improve patient outcomes and commercialize its innovative technologies. The partnership includes the validation of TeloViewNDMM, a test for predicting the relapse of newly diagnosed multiple myeloma patients, as a Laboratory Developed Test (LDT).
For further insights into TSE:TELO stock, check out TipRanks’ Stock Analysis page.
Trending Articles:
Looking for a trading platform? Check out TipRanks' Best Online Brokers guide, and find the ideal broker for your trades.
Report an Issue